1.
Golub T. Counterpoint: Data first. Nature. 2010;464(7289):679. doi:10.1038/464679a.
1.
Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54-61. doi:10.1056/NEJMoa1508887.
1.
Martyn DC, Nijjar A, Celatka CA, et al. Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010;20(1):228-31. doi:10.1016/j.bmcl.2009.10.133.
1.
Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8. doi:10.1126/science.aad5214.
1.
Du J, Bernasconi P, Clauser KR, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009;27(1):77-83. doi:10.1038/nbt.1513.
1.
Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016;167(1):171-186.e15. doi:10.1016/j.cell.2016.08.057.
1.
Tam WF, Gu T-L, Chen J, et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood. 2008;112(5):1981-92. doi:10.1182/blood-2007-07-103010.
1.
Basarab GS, Doig P, Galullo V, et al. Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914). J Med Chem. 2015;58(15):6264-82. doi:10.1021/acs.jmedchem.5b00863.
1.
Wen Q, Goldenson B, Silver SJ, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012;150(3):575-89. doi:10.1016/j.cell.2012.06.032.
1.
Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73(16):5195-205. doi:10.1158/0008-5472.CAN-12-3950.